Substitution of the transmembrane domain of Vpu in simian–human immunodeficiency virus (SHIV KU1bMC33) with that of M2 of influenza A results in a virus that is sensitive to inhibitors of the M2 ion channel and is pathogenic for pig-tailed macaques
The Vpu protein of human immunodeficiency virus type 1 has been shown to shunt the CD4 receptor molecule to the proteasome for degradation and to enhance virus release from infected cells. The exact mechanism by which the Vpu protein enhances virus release is currently unknown but some investigators...
Gespeichert in:
Veröffentlicht in: | Virology (New York, N.Y.) N.Y.), 2006-01, Vol.344 (2), p.541-559 |
---|---|
Hauptverfasser: | , , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 559 |
---|---|
container_issue | 2 |
container_start_page | 541 |
container_title | Virology (New York, N.Y.) |
container_volume | 344 |
creator | Hout, David R. Gomez, Melissa L. Pacyniak, Erik Gomez, Lisa M. Fegley, Barbara Mulcahy, Ellyn R. Hill, M. Sarah Culley, Nathan Pinson, David M. Nothnick, Warren Powers, Michael F. Wong, Scott W. Stephens, Edward B. |
description | The Vpu protein of human immunodeficiency virus type 1 has been shown to shunt the CD4 receptor molecule to the proteasome for degradation and to enhance virus release from infected cells. The exact mechanism by which the Vpu protein enhances virus release is currently unknown but some investigators have shown that this function is associated with the transmembrane domain and potential ion channel properties. In this study, we determined if the transmembrane domain of Vpu could be functionally substituted with that of the prototypical viroporin, the M2 protein of influenza A virus. We constructed chimeric
vpu gene in which the transmembrane domain of Vpu was replaced with that of the M2 protein of influenza. This chimeric
vpu gene was substituted for the
vpu gene in the genome of a pathogenic simian human immunodeficiency virus, SHIV
KU-1bMC33. The resulting virus, SHIV
M2, synthesized a Vpu protein that had a slightly different M
r compared to the parental SHIV
KU-1bMC33, reflecting the different sizes of the two Vpu proteins. The SHIV
M2 was shown to replicate with slightly reduced kinetics when compared to the parental SHIV
KU-1bMC33 but electron microscopy revealed that the site of maturation was similar to the parental virus SHIV
KU1bMC33. We show that the replication and spread of SHIV
M2 could be blocked with the antiviral drug rimantadine, which is known to target the M2 ion channel. Our results indicate a dose dependent inhibition of SHIV
M2 with 100 μM rimantadine resulting in a >95% decrease in p27 released into the culture medium. Rimantadine did not affect the replication of the parental SHIV
KU-1bMC33. Examination of SHIV
M2-infected cells treated with 50 μM rimantadine revealed numerous viral particles associated with the cell plasma membrane and within intracytoplasmic vesicles, which is similar to HIV-1 mutants lacking a functional
vpu. To determine if SHIV
M2 was as pathogenic as the parental SHIV
KU-1bMC33 virus, two pig-tailed macaques were inoculated and followed for up to 8 months. Both pig-tailed macaques developed severe CD4
+ T cell loss within 1 month of inoculation, high viral loads, and histological lesions consistent with lymphoid depletion similar to the parental SHIV
KU-1bMC33. Taken together, these results indicate for the first time that the TM domain of the Vpu protein can be functionally substituted with the TM of M2 of influenza A virus, and shows that compounds that target the TM domain of Vpu protein of HIV-1 could ser |
doi_str_mv | 10.1016/j.virol.2005.08.022 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_67618109</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0042682205004691</els_id><sourcerecordid>67618109</sourcerecordid><originalsourceid>FETCH-LOGICAL-c402t-77477515e9a6b28e1b1a92bd1e39ac458d0883dfb311b88b1cdf92d4340ce143</originalsourceid><addsrcrecordid>eNp9UctuFDEQHCEQWQJfgIR8QuEwi-2ZnceBQ7QCEpGIQ0KulsfuyfRqxl78WBRO_AN_yGdwwrO7iBsXt62uqi53ZdlLRpeMsurtZrlDZ8clp3S1pM2Scv4oWzDaVjktSvY4W1Ba8rxqOD_Jnnm_oeld1_RpdsIq1ra0LhfZ75vY-YAhBrSG2J6EAUhw0vgJpi5VINpOEve9u20k6eZxQml-_fg5xEkagtMUjdXQo0Iw6oEkW9GTs5uLyzvy6QvrrtdF8YZ8wzAkdRlmpWs-n2j6MYL5Lsk5ceDjGPysL48KezB64sF4DLhLxmzqD9hhsM7_dZu0Zu9qkMbASKTRM2krw2DvwaAivXVki_d5kDiCJpNU8msE_zx70svRw4tjPc1uP7y_XV_kV58_Xq7Pr3JVUh7yuk5LW7EVtLLqeAOsY7LlnWZQtFKVq0bTpil03xWMdU3TMaX7luuyKKkCVhan2euD7NbZeWwQE3oF45h2a6MXVV2xJqWWgMUBqJz13kEvtg4n6R4Eo2JOXGzEPnExJy5oI1LiifXqKB-7CfQ_zjHiBHh3AED64w7BCb_PCTQ6UEFoi_8d8ActA8MU</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>67618109</pqid></control><display><type>article</type><title>Substitution of the transmembrane domain of Vpu in simian–human immunodeficiency virus (SHIV KU1bMC33) with that of M2 of influenza A results in a virus that is sensitive to inhibitors of the M2 ion channel and is pathogenic for pig-tailed macaques</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Hout, David R. ; Gomez, Melissa L. ; Pacyniak, Erik ; Gomez, Lisa M. ; Fegley, Barbara ; Mulcahy, Ellyn R. ; Hill, M. Sarah ; Culley, Nathan ; Pinson, David M. ; Nothnick, Warren ; Powers, Michael F. ; Wong, Scott W. ; Stephens, Edward B.</creator><creatorcontrib>Hout, David R. ; Gomez, Melissa L. ; Pacyniak, Erik ; Gomez, Lisa M. ; Fegley, Barbara ; Mulcahy, Ellyn R. ; Hill, M. Sarah ; Culley, Nathan ; Pinson, David M. ; Nothnick, Warren ; Powers, Michael F. ; Wong, Scott W. ; Stephens, Edward B.</creatorcontrib><description>The Vpu protein of human immunodeficiency virus type 1 has been shown to shunt the CD4 receptor molecule to the proteasome for degradation and to enhance virus release from infected cells. The exact mechanism by which the Vpu protein enhances virus release is currently unknown but some investigators have shown that this function is associated with the transmembrane domain and potential ion channel properties. In this study, we determined if the transmembrane domain of Vpu could be functionally substituted with that of the prototypical viroporin, the M2 protein of influenza A virus. We constructed chimeric
vpu gene in which the transmembrane domain of Vpu was replaced with that of the M2 protein of influenza. This chimeric
vpu gene was substituted for the
vpu gene in the genome of a pathogenic simian human immunodeficiency virus, SHIV
KU-1bMC33. The resulting virus, SHIV
M2, synthesized a Vpu protein that had a slightly different M
r compared to the parental SHIV
KU-1bMC33, reflecting the different sizes of the two Vpu proteins. The SHIV
M2 was shown to replicate with slightly reduced kinetics when compared to the parental SHIV
KU-1bMC33 but electron microscopy revealed that the site of maturation was similar to the parental virus SHIV
KU1bMC33. We show that the replication and spread of SHIV
M2 could be blocked with the antiviral drug rimantadine, which is known to target the M2 ion channel. Our results indicate a dose dependent inhibition of SHIV
M2 with 100 μM rimantadine resulting in a >95% decrease in p27 released into the culture medium. Rimantadine did not affect the replication of the parental SHIV
KU-1bMC33. Examination of SHIV
M2-infected cells treated with 50 μM rimantadine revealed numerous viral particles associated with the cell plasma membrane and within intracytoplasmic vesicles, which is similar to HIV-1 mutants lacking a functional
vpu. To determine if SHIV
M2 was as pathogenic as the parental SHIV
KU-1bMC33 virus, two pig-tailed macaques were inoculated and followed for up to 8 months. Both pig-tailed macaques developed severe CD4
+ T cell loss within 1 month of inoculation, high viral loads, and histological lesions consistent with lymphoid depletion similar to the parental SHIV
KU-1bMC33. Taken together, these results indicate for the first time that the TM domain of the Vpu protein can be functionally substituted with the TM of M2 of influenza A virus, and shows that compounds that target the TM domain of Vpu protein of HIV-1 could serve as novel anti-HIV-1 drugs.</description><identifier>ISSN: 0042-6822</identifier><identifier>EISSN: 1096-0341</identifier><identifier>DOI: 10.1016/j.virol.2005.08.022</identifier><identifier>PMID: 16199074</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Amino Acid Sequence ; Animals ; CD4 Antigens - metabolism ; Cell Line ; Gene Expression Regulation, Viral ; Human Immunodeficiency Virus Proteins ; Lymphocytes - ultrastructure ; Lymphocytes - virology ; M2 protein ; Macaca nemestrina - virology ; Molecular Sequence Data ; Pathogenesis ; Protein Engineering ; Protein Structure, Tertiary ; Protein Transport ; Recombinant Fusion Proteins - chemistry ; Recombinant Fusion Proteins - genetics ; Recombinant Fusion Proteins - metabolism ; RNA, Viral - blood ; SHIV ; Simian Acquired Immunodeficiency Syndrome - virology ; Simian Immunodeficiency Virus - genetics ; Simian Immunodeficiency Virus - pathogenicity ; Viral Load ; Viral Matrix Proteins - antagonists & inhibitors ; Viral Matrix Proteins - chemistry ; Viral Matrix Proteins - genetics ; Viral Matrix Proteins - metabolism ; Viral Regulatory and Accessory Proteins - chemistry ; Viral Regulatory and Accessory Proteins - genetics ; Viral Regulatory and Accessory Proteins - metabolism ; Viroporin ; Vpu</subject><ispartof>Virology (New York, N.Y.), 2006-01, Vol.344 (2), p.541-559</ispartof><rights>2005 Elsevier Inc.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c402t-77477515e9a6b28e1b1a92bd1e39ac458d0883dfb311b88b1cdf92d4340ce143</citedby><cites>FETCH-LOGICAL-c402t-77477515e9a6b28e1b1a92bd1e39ac458d0883dfb311b88b1cdf92d4340ce143</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0042682205004691$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16199074$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Hout, David R.</creatorcontrib><creatorcontrib>Gomez, Melissa L.</creatorcontrib><creatorcontrib>Pacyniak, Erik</creatorcontrib><creatorcontrib>Gomez, Lisa M.</creatorcontrib><creatorcontrib>Fegley, Barbara</creatorcontrib><creatorcontrib>Mulcahy, Ellyn R.</creatorcontrib><creatorcontrib>Hill, M. Sarah</creatorcontrib><creatorcontrib>Culley, Nathan</creatorcontrib><creatorcontrib>Pinson, David M.</creatorcontrib><creatorcontrib>Nothnick, Warren</creatorcontrib><creatorcontrib>Powers, Michael F.</creatorcontrib><creatorcontrib>Wong, Scott W.</creatorcontrib><creatorcontrib>Stephens, Edward B.</creatorcontrib><title>Substitution of the transmembrane domain of Vpu in simian–human immunodeficiency virus (SHIV KU1bMC33) with that of M2 of influenza A results in a virus that is sensitive to inhibitors of the M2 ion channel and is pathogenic for pig-tailed macaques</title><title>Virology (New York, N.Y.)</title><addtitle>Virology</addtitle><description>The Vpu protein of human immunodeficiency virus type 1 has been shown to shunt the CD4 receptor molecule to the proteasome for degradation and to enhance virus release from infected cells. The exact mechanism by which the Vpu protein enhances virus release is currently unknown but some investigators have shown that this function is associated with the transmembrane domain and potential ion channel properties. In this study, we determined if the transmembrane domain of Vpu could be functionally substituted with that of the prototypical viroporin, the M2 protein of influenza A virus. We constructed chimeric
vpu gene in which the transmembrane domain of Vpu was replaced with that of the M2 protein of influenza. This chimeric
vpu gene was substituted for the
vpu gene in the genome of a pathogenic simian human immunodeficiency virus, SHIV
KU-1bMC33. The resulting virus, SHIV
M2, synthesized a Vpu protein that had a slightly different M
r compared to the parental SHIV
KU-1bMC33, reflecting the different sizes of the two Vpu proteins. The SHIV
M2 was shown to replicate with slightly reduced kinetics when compared to the parental SHIV
KU-1bMC33 but electron microscopy revealed that the site of maturation was similar to the parental virus SHIV
KU1bMC33. We show that the replication and spread of SHIV
M2 could be blocked with the antiviral drug rimantadine, which is known to target the M2 ion channel. Our results indicate a dose dependent inhibition of SHIV
M2 with 100 μM rimantadine resulting in a >95% decrease in p27 released into the culture medium. Rimantadine did not affect the replication of the parental SHIV
KU-1bMC33. Examination of SHIV
M2-infected cells treated with 50 μM rimantadine revealed numerous viral particles associated with the cell plasma membrane and within intracytoplasmic vesicles, which is similar to HIV-1 mutants lacking a functional
vpu. To determine if SHIV
M2 was as pathogenic as the parental SHIV
KU-1bMC33 virus, two pig-tailed macaques were inoculated and followed for up to 8 months. Both pig-tailed macaques developed severe CD4
+ T cell loss within 1 month of inoculation, high viral loads, and histological lesions consistent with lymphoid depletion similar to the parental SHIV
KU-1bMC33. Taken together, these results indicate for the first time that the TM domain of the Vpu protein can be functionally substituted with the TM of M2 of influenza A virus, and shows that compounds that target the TM domain of Vpu protein of HIV-1 could serve as novel anti-HIV-1 drugs.</description><subject>Amino Acid Sequence</subject><subject>Animals</subject><subject>CD4 Antigens - metabolism</subject><subject>Cell Line</subject><subject>Gene Expression Regulation, Viral</subject><subject>Human Immunodeficiency Virus Proteins</subject><subject>Lymphocytes - ultrastructure</subject><subject>Lymphocytes - virology</subject><subject>M2 protein</subject><subject>Macaca nemestrina - virology</subject><subject>Molecular Sequence Data</subject><subject>Pathogenesis</subject><subject>Protein Engineering</subject><subject>Protein Structure, Tertiary</subject><subject>Protein Transport</subject><subject>Recombinant Fusion Proteins - chemistry</subject><subject>Recombinant Fusion Proteins - genetics</subject><subject>Recombinant Fusion Proteins - metabolism</subject><subject>RNA, Viral - blood</subject><subject>SHIV</subject><subject>Simian Acquired Immunodeficiency Syndrome - virology</subject><subject>Simian Immunodeficiency Virus - genetics</subject><subject>Simian Immunodeficiency Virus - pathogenicity</subject><subject>Viral Load</subject><subject>Viral Matrix Proteins - antagonists & inhibitors</subject><subject>Viral Matrix Proteins - chemistry</subject><subject>Viral Matrix Proteins - genetics</subject><subject>Viral Matrix Proteins - metabolism</subject><subject>Viral Regulatory and Accessory Proteins - chemistry</subject><subject>Viral Regulatory and Accessory Proteins - genetics</subject><subject>Viral Regulatory and Accessory Proteins - metabolism</subject><subject>Viroporin</subject><subject>Vpu</subject><issn>0042-6822</issn><issn>1096-0341</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2006</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9UctuFDEQHCEQWQJfgIR8QuEwi-2ZnceBQ7QCEpGIQ0KulsfuyfRqxl78WBRO_AN_yGdwwrO7iBsXt62uqi53ZdlLRpeMsurtZrlDZ8clp3S1pM2Scv4oWzDaVjktSvY4W1Ba8rxqOD_Jnnm_oeld1_RpdsIq1ra0LhfZ75vY-YAhBrSG2J6EAUhw0vgJpi5VINpOEve9u20k6eZxQml-_fg5xEkagtMUjdXQo0Iw6oEkW9GTs5uLyzvy6QvrrtdF8YZ8wzAkdRlmpWs-n2j6MYL5Lsk5ceDjGPysL48KezB64sF4DLhLxmzqD9hhsM7_dZu0Zu9qkMbASKTRM2krw2DvwaAivXVki_d5kDiCJpNU8msE_zx70svRw4tjPc1uP7y_XV_kV58_Xq7Pr3JVUh7yuk5LW7EVtLLqeAOsY7LlnWZQtFKVq0bTpil03xWMdU3TMaX7luuyKKkCVhan2euD7NbZeWwQE3oF45h2a6MXVV2xJqWWgMUBqJz13kEvtg4n6R4Eo2JOXGzEPnExJy5oI1LiifXqKB-7CfQ_zjHiBHh3AED64w7BCb_PCTQ6UEFoi_8d8ActA8MU</recordid><startdate>20060120</startdate><enddate>20060120</enddate><creator>Hout, David R.</creator><creator>Gomez, Melissa L.</creator><creator>Pacyniak, Erik</creator><creator>Gomez, Lisa M.</creator><creator>Fegley, Barbara</creator><creator>Mulcahy, Ellyn R.</creator><creator>Hill, M. Sarah</creator><creator>Culley, Nathan</creator><creator>Pinson, David M.</creator><creator>Nothnick, Warren</creator><creator>Powers, Michael F.</creator><creator>Wong, Scott W.</creator><creator>Stephens, Edward B.</creator><general>Elsevier Inc</general><scope>6I.</scope><scope>AAFTH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20060120</creationdate><title>Substitution of the transmembrane domain of Vpu in simian–human immunodeficiency virus (SHIV KU1bMC33) with that of M2 of influenza A results in a virus that is sensitive to inhibitors of the M2 ion channel and is pathogenic for pig-tailed macaques</title><author>Hout, David R. ; Gomez, Melissa L. ; Pacyniak, Erik ; Gomez, Lisa M. ; Fegley, Barbara ; Mulcahy, Ellyn R. ; Hill, M. Sarah ; Culley, Nathan ; Pinson, David M. ; Nothnick, Warren ; Powers, Michael F. ; Wong, Scott W. ; Stephens, Edward B.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c402t-77477515e9a6b28e1b1a92bd1e39ac458d0883dfb311b88b1cdf92d4340ce143</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2006</creationdate><topic>Amino Acid Sequence</topic><topic>Animals</topic><topic>CD4 Antigens - metabolism</topic><topic>Cell Line</topic><topic>Gene Expression Regulation, Viral</topic><topic>Human Immunodeficiency Virus Proteins</topic><topic>Lymphocytes - ultrastructure</topic><topic>Lymphocytes - virology</topic><topic>M2 protein</topic><topic>Macaca nemestrina - virology</topic><topic>Molecular Sequence Data</topic><topic>Pathogenesis</topic><topic>Protein Engineering</topic><topic>Protein Structure, Tertiary</topic><topic>Protein Transport</topic><topic>Recombinant Fusion Proteins - chemistry</topic><topic>Recombinant Fusion Proteins - genetics</topic><topic>Recombinant Fusion Proteins - metabolism</topic><topic>RNA, Viral - blood</topic><topic>SHIV</topic><topic>Simian Acquired Immunodeficiency Syndrome - virology</topic><topic>Simian Immunodeficiency Virus - genetics</topic><topic>Simian Immunodeficiency Virus - pathogenicity</topic><topic>Viral Load</topic><topic>Viral Matrix Proteins - antagonists & inhibitors</topic><topic>Viral Matrix Proteins - chemistry</topic><topic>Viral Matrix Proteins - genetics</topic><topic>Viral Matrix Proteins - metabolism</topic><topic>Viral Regulatory and Accessory Proteins - chemistry</topic><topic>Viral Regulatory and Accessory Proteins - genetics</topic><topic>Viral Regulatory and Accessory Proteins - metabolism</topic><topic>Viroporin</topic><topic>Vpu</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hout, David R.</creatorcontrib><creatorcontrib>Gomez, Melissa L.</creatorcontrib><creatorcontrib>Pacyniak, Erik</creatorcontrib><creatorcontrib>Gomez, Lisa M.</creatorcontrib><creatorcontrib>Fegley, Barbara</creatorcontrib><creatorcontrib>Mulcahy, Ellyn R.</creatorcontrib><creatorcontrib>Hill, M. Sarah</creatorcontrib><creatorcontrib>Culley, Nathan</creatorcontrib><creatorcontrib>Pinson, David M.</creatorcontrib><creatorcontrib>Nothnick, Warren</creatorcontrib><creatorcontrib>Powers, Michael F.</creatorcontrib><creatorcontrib>Wong, Scott W.</creatorcontrib><creatorcontrib>Stephens, Edward B.</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Virology (New York, N.Y.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hout, David R.</au><au>Gomez, Melissa L.</au><au>Pacyniak, Erik</au><au>Gomez, Lisa M.</au><au>Fegley, Barbara</au><au>Mulcahy, Ellyn R.</au><au>Hill, M. Sarah</au><au>Culley, Nathan</au><au>Pinson, David M.</au><au>Nothnick, Warren</au><au>Powers, Michael F.</au><au>Wong, Scott W.</au><au>Stephens, Edward B.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Substitution of the transmembrane domain of Vpu in simian–human immunodeficiency virus (SHIV KU1bMC33) with that of M2 of influenza A results in a virus that is sensitive to inhibitors of the M2 ion channel and is pathogenic for pig-tailed macaques</atitle><jtitle>Virology (New York, N.Y.)</jtitle><addtitle>Virology</addtitle><date>2006-01-20</date><risdate>2006</risdate><volume>344</volume><issue>2</issue><spage>541</spage><epage>559</epage><pages>541-559</pages><issn>0042-6822</issn><eissn>1096-0341</eissn><abstract>The Vpu protein of human immunodeficiency virus type 1 has been shown to shunt the CD4 receptor molecule to the proteasome for degradation and to enhance virus release from infected cells. The exact mechanism by which the Vpu protein enhances virus release is currently unknown but some investigators have shown that this function is associated with the transmembrane domain and potential ion channel properties. In this study, we determined if the transmembrane domain of Vpu could be functionally substituted with that of the prototypical viroporin, the M2 protein of influenza A virus. We constructed chimeric
vpu gene in which the transmembrane domain of Vpu was replaced with that of the M2 protein of influenza. This chimeric
vpu gene was substituted for the
vpu gene in the genome of a pathogenic simian human immunodeficiency virus, SHIV
KU-1bMC33. The resulting virus, SHIV
M2, synthesized a Vpu protein that had a slightly different M
r compared to the parental SHIV
KU-1bMC33, reflecting the different sizes of the two Vpu proteins. The SHIV
M2 was shown to replicate with slightly reduced kinetics when compared to the parental SHIV
KU-1bMC33 but electron microscopy revealed that the site of maturation was similar to the parental virus SHIV
KU1bMC33. We show that the replication and spread of SHIV
M2 could be blocked with the antiviral drug rimantadine, which is known to target the M2 ion channel. Our results indicate a dose dependent inhibition of SHIV
M2 with 100 μM rimantadine resulting in a >95% decrease in p27 released into the culture medium. Rimantadine did not affect the replication of the parental SHIV
KU-1bMC33. Examination of SHIV
M2-infected cells treated with 50 μM rimantadine revealed numerous viral particles associated with the cell plasma membrane and within intracytoplasmic vesicles, which is similar to HIV-1 mutants lacking a functional
vpu. To determine if SHIV
M2 was as pathogenic as the parental SHIV
KU-1bMC33 virus, two pig-tailed macaques were inoculated and followed for up to 8 months. Both pig-tailed macaques developed severe CD4
+ T cell loss within 1 month of inoculation, high viral loads, and histological lesions consistent with lymphoid depletion similar to the parental SHIV
KU-1bMC33. Taken together, these results indicate for the first time that the TM domain of the Vpu protein can be functionally substituted with the TM of M2 of influenza A virus, and shows that compounds that target the TM domain of Vpu protein of HIV-1 could serve as novel anti-HIV-1 drugs.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>16199074</pmid><doi>10.1016/j.virol.2005.08.022</doi><tpages>19</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0042-6822 |
ispartof | Virology (New York, N.Y.), 2006-01, Vol.344 (2), p.541-559 |
issn | 0042-6822 1096-0341 |
language | eng |
recordid | cdi_proquest_miscellaneous_67618109 |
source | MEDLINE; Elsevier ScienceDirect Journals; EZB-FREE-00999 freely available EZB journals |
subjects | Amino Acid Sequence Animals CD4 Antigens - metabolism Cell Line Gene Expression Regulation, Viral Human Immunodeficiency Virus Proteins Lymphocytes - ultrastructure Lymphocytes - virology M2 protein Macaca nemestrina - virology Molecular Sequence Data Pathogenesis Protein Engineering Protein Structure, Tertiary Protein Transport Recombinant Fusion Proteins - chemistry Recombinant Fusion Proteins - genetics Recombinant Fusion Proteins - metabolism RNA, Viral - blood SHIV Simian Acquired Immunodeficiency Syndrome - virology Simian Immunodeficiency Virus - genetics Simian Immunodeficiency Virus - pathogenicity Viral Load Viral Matrix Proteins - antagonists & inhibitors Viral Matrix Proteins - chemistry Viral Matrix Proteins - genetics Viral Matrix Proteins - metabolism Viral Regulatory and Accessory Proteins - chemistry Viral Regulatory and Accessory Proteins - genetics Viral Regulatory and Accessory Proteins - metabolism Viroporin Vpu |
title | Substitution of the transmembrane domain of Vpu in simian–human immunodeficiency virus (SHIV KU1bMC33) with that of M2 of influenza A results in a virus that is sensitive to inhibitors of the M2 ion channel and is pathogenic for pig-tailed macaques |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-08T11%3A30%3A04IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Substitution%20of%20the%20transmembrane%20domain%20of%20Vpu%20in%20simian%E2%80%93human%20immunodeficiency%20virus%20(SHIV%20KU1bMC33)%20with%20that%20of%20M2%20of%20influenza%20A%20results%20in%20a%20virus%20that%20is%20sensitive%20to%20inhibitors%20of%20the%20M2%20ion%20channel%20and%20is%20pathogenic%20for%20pig-tailed%20macaques&rft.jtitle=Virology%20(New%20York,%20N.Y.)&rft.au=Hout,%20David%20R.&rft.date=2006-01-20&rft.volume=344&rft.issue=2&rft.spage=541&rft.epage=559&rft.pages=541-559&rft.issn=0042-6822&rft.eissn=1096-0341&rft_id=info:doi/10.1016/j.virol.2005.08.022&rft_dat=%3Cproquest_cross%3E67618109%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=67618109&rft_id=info:pmid/16199074&rft_els_id=S0042682205004691&rfr_iscdi=true |